SREBF2 and Disorder of lipid metabolism: These findings indicate that LBT effectively mitigates hepatic lipid metabolic disorders by downregulating the expression of genes related to cholesterol synthesis (SREBP2 and HMGCR) and upregulating the expression of genes involved in cholesterol efflux and reverse cholesterol transport (ABCA1, ABCG5, ABCG8, LCAT, LDLR, and APOA1).